Pharmaceuticals & Therapeutics

The neuro-focused biotech just acquired a late-stage cancer drug, securing massive funding. Is this a brilliant diversification or a high-stakes gamble?

Bolstered by positive clinical data and top investors, Kalaris Therapeutics extends its runway to advance TH103, a next-gen treatment for neovascular AMD.

Early Phase 1a data for Kalaris's new nAMD drug shows significant vision improvement and potential for extended durability, aiming to reduce patient burden.

A key trial update de-risks Tenax Therapeutics' pivotal study for a novel heart failure therapy, boosting confidence in its path to market.

Dartmouth Cancer Center gains a top designation for using GammaTile, an innovative implant that delivers immediate radiation during brain tumor surgery.

A new study reveals a tissue allograft, AmchoPlast™, triples healing rates for diabetic foot ulcers, offering a major breakthrough for a common complication.

Can-Fite BioPharma eyes key 2026 data readouts for its late-stage oral drugs targeting advanced liver cancer, psoriasis, and other unmet medical needs.

The world's largest bamboo resort opens in a Vietnamese heritage site, blending Hmong culture with advanced wellness for a new kind of regenerative travel.

Zephyrus Innovations just got FDA clearance for VaporShield, a device protecting nurses from drug exposure. It’s a story of safety, market disruption, and efficiency.

A breakthrough clinical trial and a savvy financial move could net Fractyl Health $18M to advance its novel obesity treatment beyond the GLP-1 boom.

Verastem Oncology taps industry heavyweights for its leadership, signaling a bold new strategy to accelerate its cancer pipeline and grow its market share.

Tiziana's CEO doubles down with a major share purchase, signaling deep faith in a novel MS drug, even as market signals send mixed messages.

Viceroy Hotels isn't just hiring executives; it's assembling a team of specialists to redefine experiential luxury and accelerate its global expansion.

As Spruce Biosciences preps its rare disease drug for FDA review, the addition of a commercial veteran signals a high-stakes shift from R&D to market.

Quince Therapeutics' Phase 3 trial completion for Ataxia-Telangiectasia offers hope, but the real story is its innovative red blood cell drug delivery platform.

How a strategic pharma pact between Duchesnay and Mochida to bring a vital pregnancy drug to Japan offers a blueprint for stable returns in complex markets.

A pivotal trial success in lupus for BTK inhibitor orelabrutinib not only offers new hope for patients but also validates Zenas BioPharma's strategy.

FDA greenlights the first precision therapy for BRCA2-mutated mCSPC, a highly aggressive prostate cancer, slashing progression risk by 54%.

Updated trial results for Lilly's Inluriyo-Verzenio combo extend life without chemo, positioning the firm for dominance in a competitive oncology market.

Amid a $2.37B buyout, Weiss Asset Management's increased stake in Avadel Pharma raises questions. Is it a vote of confidence or a strategic power play?